Search
forLearn
5 / 801 resultslearn ACETYL TETRAPEPTIDE-2
learn PTD-DBM
learn Thymosin Beta 4
learn L- Arginine Alpha- Ketoglutarate
Research
5 / 107 results
research The effects of GPR40 agonists on hair growth are mediated by ANGPTL4
GPR40 agonists help hair growth through the protein ANGPTL4.
research CD34 + cell–derived fibroblast-macrophage cross-talk drives limb ischemia recovery through the OSM-ANGPTL signaling axis
CD34+ cells help heal damaged limbs by promoting blood vessel growth.
research In vitro hair growth-promoting effects of araliadiol via the p38/PPAR-γ signaling pathway in human hair follicle stem cells and dermal papilla cells
Araliadiol may promote hair growth like minoxidil without being toxic.
research Cross-Signaling Between Hair Follicle Stem Cells And Dermal Lymphatic Vessels: A Systematic Review
Targeting hair follicle stem cell and lymphatic vessel signaling may help treat hair loss and improve wound healing.
research Cross-Signaling Between Hair Follicle Stem Cells And Dermal Lymphatic Vessels: A Systematic Review
Targeting hair follicle stem cell and lymphatic vessel signaling may help treat hair loss and improve wound healing.
Community Join
5 / 1000+ resultscommunity mallia therapeutics 8T3 scd83 molecule for ffa/lpp mainly and aga
A user applied the 8T3 product for hair loss, targeting LPP and AGA, and plans to update on its effectiveness. The product uses a saline buffered phosphate vehicle, suitable for those intolerant to ethanolic vehicles.
community AH-001 another topical AR degrader beside GT20029, completed Phase I
AH-001 is a new topical treatment designed to degrade androgen receptors, targeting the root cause of androgenetic alopecia without the side effects of oral treatments like finasteride. It has shown a strong safety profile and good local tolerability in early trials.
community PELAGE PHASE 2 TRIALS FOR PP405 - Volunteers Needed
PP405 is a topical gel being tested for hair regrowth in adults with androgenetic alopecia. Volunteers aged 18-55 are needed for a 16-week trial in several US locations.
community GT20029 China Phase II Trial For AGA Reached Primary Endpoint
The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.
community Kintor Pharmaceutical Announces AR-PROTAC (GT20029) Approved for Acne and Androgenic Alopecia Clinical Trials in China
The conversation discusses the approval of Kintor Pharmaceutical's AR-PROTAC (GT20029) for clinical trials in China for acne and androgenic alopecia. One user expresses optimism about new treatments being developed and seeks clarification on how the new drug works, specifically if it temporarily degrades the AR protein to reduce DHT sensitivity in hair follicles.